Vivek Subbiah: Comments on the ESMO Presidential Symposium Precision Oncology trials and DRUP-like trials

Vivek Subbiah shared a post on LinkedIn by ESMO adding:

“Hot off the press Read my comments on the ESMO Presidential Symposium Precision Oncology trials and DRUP-like trials presented at ESMO24
ESMO24: Drug rediscovery trials facilitate access to Precision Oncology and highlight the importance of integrating comprehensive Genomic Profiling into clinical practice across a broad range of tumour types ESMO Daily Reporter.”

Quoting ESMO’s post below:

“Evidence for the feasibility, early efficacy and safety of incorporating comprehensive Genomic Profiling into clinical practice to provide personalised treatments based on Drug Rediscovery Protocol-like Clinical Trials (DLCTs) was presented at ESMO24. DLCTs explore the effects of biomarker-driven treatments outside their approved indication(s) across a broad range of tumour types, thus enabling the study of Precision Oncology in large patient numbers, according to Vivek Subbiah.

Source: Vivek Subbiah/LinkedIn and ESMO/LinkedIn